Human Cell Biology of Genetic Variants in Alzheimer's Disease (R01) | RFA AG 17 053

Opportunity Information: Apply for RFA AG 17 053

The National Institutes of Health (NIH) funding opportunity titled "Human Cell Biology of Genetic Variants in Alzheimer's Disease (R01)" (Funding Opportunity Number RFA-AG-17-053; CFDA 93.866) is a discretionary research grant aimed at clarifying how specific human genetic variants linked to Alzheimer's disease (AD) actually influence cell behavior in the brain. The central idea is to move beyond statistical associations found in large human genetics studies and instead demonstrate causal, functional connections between AD-associated variants and measurable biological changes in human neural cells. By doing this, the program seeks to sharpen understanding of AD disease mechanisms and help identify molecular targets that could be relevant for therapy development.

The scientific focus is on establishing genotype-phenotype relationships for variants suspected of changing AD risk. These variants often come from genome-wide association studies (GWAS) and genome sequencing efforts that can pinpoint regions of the genome correlated with disease risk but do not automatically reveal which gene is affected, what direction the effect goes in, or what cellular pathway is disrupted. This FOA emphasizes functional follow-up, meaning applicants are expected to test how these variants alter molecular and cellular phenotypes in relevant human cell types rather than relying only on computational predictions or non-human model systems.

A key requirement of the approach is the use of human induced pluripotent stem cells (iPSCs) or other human cell reprogramming methods to generate neural cells for experiments. In practical terms, this typically means deriving or engineering human cell lines that carry specific AD-linked genetic variants and differentiating them into neurons and/or glial cell types (such as astrocytes, microglia-like cells, or oligodendrocytes) so investigators can observe variant-driven effects in a human cellular context. The underlying rationale is that AD risk variants may exert their effects in ways that are difficult to capture in animal models or immortalized cell lines, and that human reprogrammed neural systems can better reflect the biology of human brain cells, including relevant gene regulation and disease-relevant pathways.

The outcomes NIH is looking for are experimentally supported links between AD genetics and cellular mechanisms. That can include molecular phenotypes (for example, altered gene expression programs, splicing changes, epigenetic states, protein levels, or pathway activation) as well as biological cell phenotypes (for example, changes in neuronal function, synaptic biology, cellular stress responses, inflammatory signaling in glia, protein processing and trafficking, lipid metabolism, or other cell behaviors plausibly connected to AD etiology). The FOA frames these results as a way to gain greater insight into molecular targets contributing to the origins and progression of Alzheimer's disease, effectively building a bridge between human genetic discovery and mechanistic biology in human neural cells.

This opportunity uses the NIH R01 mechanism, meaning it is structured to support substantial, hypothesis-driven research projects with clearly defined aims, rigorous experimental design, and strong justification for the chosen models and readouts. The awarding agency is NIH, and the funding activity category is Health. The listed original closing date for the opportunity was February 10, 2017, and the opportunity record indicates a creation date of October 21, 2016. Award ceiling and expected number of awards are not specified in the provided source data.

Eligibility is broad and includes many types of U.S. organizations and, notably, certain non-U.S. entities as well. Eligible applicants include state, county, city, township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; other Native American tribal organizations; public housing authorities/Indian housing authorities; nonprofit organizations with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations other than small businesses; small businesses; and other unspecified eligible entities. The announcement also explicitly highlights additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions; Asian American, Native American, and Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); eligible federal agencies; faith-based or community-based organizations; Indian/Native American tribal governments other than federally recognized ones; regional organizations; U.S. territories or possessions; and non-domestic (non-U.S.) entities (foreign organizations). In effect, NIH designed the eligibility rules to accommodate a wide range of academic, nonprofit, governmental, and industry participants, including institutions serving underrepresented communities and certain international organizations.

Taken together, the FOA is best understood as a targeted push to convert AD genetic signals into experimentally validated biology using human reprogrammed neural cell systems. The expectation is that projects will not only confirm that a variant matters, but also explain how it matters at the level of molecules, pathways, and cell function in human neural cells, thereby illuminating mechanisms that could ultimately be leveraged for diagnostics or therapeutic development.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Human Cell Biology of Genetic Variants in Alzheimer's Disease (R01)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
• This funding opportunity was created on 2016-10-21.
• Applicants must submit their applications by 2017-02-10. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for RFA AG 17 053

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: